Explore
Validate
Learn26250-1-AP
antibody from Proteintech Group
Targeting: TAOK1
FLJ14314, KIAA1361, MAP3K16, MARKK, PSK2, TAO1
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 26250-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- TAOK1 antibody
- Antibody type
- Polyclonal
- Description
- TAOK1 antibody (Cat. #26250-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse and has been validated for the following applications: IF, IHC, WB, ELISA.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Targeting TAOK1 with resveratrol inhibits esophageal squamous cell carcinoma growth in vitro and in vivo.
Phenylalanine-tRNA aminoacylation is compromised by ALS/FTD-associated C9orf72 C4G2 repeat RNA.
Neurodevelopmental disorder-associated mutations in TAOK1 reveal its function as a plasma membrane remodeling kinase.
Rnd3 interacts with TAO kinases and contributes to mitotic cell rounding and spindle positioning.
A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.
Variants in EXOSC9 Disrupt the RNA Exosome and Result in Cerebellar Atrophy with Spinal Motor Neuronopathy.
Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells.
Song M, Qu Y, Jia H, Zhang Y, Liu S, Laster KV, Choi BY, Tian J, Gu T, Chen H, Liu K, Lee MH, Dong Z
Molecular carcinogenesis 2024 May;63(5):991-1008
Molecular carcinogenesis 2024 May;63(5):991-1008
Phenylalanine-tRNA aminoacylation is compromised by ALS/FTD-associated C9orf72 C4G2 repeat RNA.
Malnar Črnigoj M, Čerček U, Yin X, Ho MT, Repic Lampret B, Neumann M, Hermann A, Rouleau G, Suter B, Mayr M, Rogelj B
Nature communications 2023 Sep 16;14(1):5764
Nature communications 2023 Sep 16;14(1):5764
Neurodevelopmental disorder-associated mutations in TAOK1 reveal its function as a plasma membrane remodeling kinase.
Beeman N, Sapre T, Ong SE, Yadav S
Science signaling 2023 Jan 3;16(766):eadd3269
Science signaling 2023 Jan 3;16(766):eadd3269
Rnd3 interacts with TAO kinases and contributes to mitotic cell rounding and spindle positioning.
Garg R, Koo CY, Infante E, Giacomini C, Ridley AJ, Morris JDH
Journal of cell science 2020 Mar 16;133(6)
Journal of cell science 2020 Mar 16;133(6)
A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.
Giacomini C, Koo CY, Yankova N, Tavares IA, Wray S, Noble W, Hanger DP, Morris JDH
Acta neuropathologica communications 2018 May 7;6(1):37
Acta neuropathologica communications 2018 May 7;6(1):37
Variants in EXOSC9 Disrupt the RNA Exosome and Result in Cerebellar Atrophy with Spinal Motor Neuronopathy.
Burns DT, Donkervoort S, Müller JS, Knierim E, Bharucha-Goebel D, Faqeih EA, Bell SK, AlFaifi AY, Monies D, Millan F, Retterer K, Dyack S, MacKay S, Morales-Gonzalez S, Giunta M, Munro B, Hudson G, Scavina M, Baker L, Massini TC, Lek M, Hu Y, Ezzo D, AlKuraya FS, Kang PB, Griffin H, Foley AR, Schuelke M, Horvath R, Bönnemann CG
American journal of human genetics 2018 May 3;102(5):858-873
American journal of human genetics 2018 May 3;102(5):858-873
Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells.
Koo CY, Giacomini C, Reyes-Corral M, Olmos Y, Tavares IA, Marson CM, Linardopoulos S, Tutt AN, Morris JDH
Molecular cancer therapeutics 2017 Nov;16(11):2410-2421
Molecular cancer therapeutics 2017 Nov;16(11):2410-2421
No comments: Submit comment
No validations: Submit validation data